Forward to Quit: A Person-centered Mobile Technology Intervention for Smoking Cessation Among Transgender Adults
Key facts
- Who runs it
- University of Colorado, Denver
- Where
- Aurora, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- People taking part
- 47 people enrolled
- Started
- 14 Oct 2025
- Expected to end
- Dec 2031
- Type of study
- Interventional
- Treatments tested
- Forward to Quit (F2Q)
- Record updated
- 30 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Identify with a gender different from sex assigned at birth
- 18+ years of age
- Report smoking at least 5 cigarettes per day
- Have smoked 100+ cigarettes in their lifetime
- Own a device that can access the Internet (e.g., tablet, smartphone)
- Speak English
- Be willing to submit biochemical samples to verify cessation
- Be willing to use a website-based intervention to help with quit attempt
- Be willing to set a quit date within 1 month of baseline assessment
- Be willing to complete 3 months post-baseline and 6 months post-baseline assessments
Who cannot take part
- Medical conditions precluding use of the carbon monoxide (CO) monitor or salivary cotinine testing
- Do not meet inclusion criteria
- Current use of pharmacotherapies for nicotine dependence
- Enrollment in another tobacco cessation program
Where in United States
- University of Colorado Anschutz Medical CampusAurora, United States
About the trial
What the trial wants to find out
This study evaluates the feasibility, acceptability, and preliminary efficacy of "Forward to Quit" (F2Q), a person-centered mobile health (mHealth) smoking cessation intervention designed specifically for transgender adults. The intervention was developed in collaboration with transgender individuals and gender-affirming healthcare providers. The study includes usability testing and a remote single-arm pilot trial. Primary outcomes include feasibility and acceptability of both the intervention and remote biochemical verification of smoking cessation. Secondary outcomes include self-reported and biochemically verified smoking cessation, as well as changes in psychosocial factors such as social support and gender affirmation. The goal is to inform a future large-scale trial and address tobacco-related health disparities in transgender populations.
The group in the trial
- F2Q InterventionTreatment being tested
Participants will receive access to the Forward to Quit (F2Q) mHealth smoking cessation intervention tailored for transgender adults
Treatment: Forward to Quit (F2Q)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 30 June 2026